ATHE

MSA drug that slowed decline 48% gets FDA nod for Phase 3 plan

Alterity Therapeutics announced FDA alignment on its pivotal Phase 3 program for ATH434, a drug candidate for Multiple System Atrophy (MSA). The FDA a...